In contrast, KIT-mutant acral and mucosal melanomas derive modest but meaningful benefit from KIT inhibitors (e.g., imatinib, nilotinib), particularly when activating mutations occur in sensitive regions such as exon 11, though responses are typically less durable than those achieved with BRAF + MEK therapy. This evidence concerns the gene MAP2K7 and melanoma.